Bacterin International Holdings (NYSE:BONE), a developer of bone graft material and antimicrobial coatings for medical application, said Tuesday its chief executive Guy Cook will present at LD Micro’s fourth annual conference, in Los Angeles.
Cook is slated to present on Thursday, December 8, 2011 at 10:30 a.m. pacific time at the Luxe Hotel, with one-on-one meetings held during the day.
In addition, the company said management will talk about its recent quarterly results and its business plan along with objectives for the rest of 2011.
The LD Micro conference brings together 101 presenting companies with more than 150 institutions focused on investing in small and micro-cap companies across an array of industries.
LD Micro is a by-invitation only newsletter firm that focuses on finding undervalued companies in the micro-cap space.
Since 2002, LD Micro has published an annual list of recommended stocks as well as comprehensive reports on select companies throughout the year.
Bacterin’s proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone repair and dermal growth. The company's medical division also develops antimicrobial coatings that inhibit contamination.
The Belgrade, Montana-based company’s shares grew 6 cents, or 2.32 percent, reaching $2.65 late Tuesday afternoon on the New York Stock Exchange.
Cook is slated to present on Thursday, December 8, 2011 at 10:30 a.m. pacific time at the Luxe Hotel, with one-on-one meetings held during the day.
In addition, the company said management will talk about its recent quarterly results and its business plan along with objectives for the rest of 2011.
The LD Micro conference brings together 101 presenting companies with more than 150 institutions focused on investing in small and micro-cap companies across an array of industries.
LD Micro is a by-invitation only newsletter firm that focuses on finding undervalued companies in the micro-cap space.
Since 2002, LD Micro has published an annual list of recommended stocks as well as comprehensive reports on select companies throughout the year.
Bacterin’s proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone repair and dermal growth. The company's medical division also develops antimicrobial coatings that inhibit contamination.
The Belgrade, Montana-based company’s shares grew 6 cents, or 2.32 percent, reaching $2.65 late Tuesday afternoon on the New York Stock Exchange.
No comments:
Post a Comment